Overview

Chemomab is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.

The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.

Chemomab is currently promoting in parallel three phase 2 studies, focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Recent News
Nov 30, 2022

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory...

Nov 14, 2022

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory...

Nov 11, 2022

─Chemomab to Host Conference Call for Investors Today, November 11 at 8:00 am ET─ TEL AVIV, Israel, Nov. 11, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage...

Nov 9, 2022

─New Findings Demonstrate CM-101's Anti-Inflammatory and Anti-Fibrotic Effects Are Highly Relevant to Inflammatory Lung Diseases─ TEL AVIV, Israel, Nov. 9, 2022 /PRNewswire/ -- Chemomab...

All News

Stock Info
NASDAQCMMB
Events
Friday, November 11, 2022
8:00am EST

Virtual Webcast and Conference Call with Q&A
Senior Management will present
Listen to the Webcast

Conference call information:
US Investors: +1 (877) 407-9208
International Investors: +1 (201) 493-6784
Conference ID: 13732524
Ask for Chemomab conference call.

Wednesday, November 9, 2022 - Friday, November 11, 2022

Venue: Crowne Plaza Woburn, Woburn, MA
Format: Oral presentation: Crossing the Divide: Leveraging Fibrosis-Inflammatory Biomarkers to Inform Clinical Trial Design
Session: Illuminating the Latest in Fibrotic Biomarkers Across Indications to Harness Predictive and Progressive Biomarkers in Clinical Development
Time: November 10, 2022, 11:00 am ET
Presenter: Adi Mor, PhD, Co-Founder & Chief Scientific Officer, Chemomab
Information: https://afdd-summit.com/

A copy of the presentation will be available at the R&D section of Chemomab’s website (www.chemomab.com).

All Events

Featured Presentations

Download

Chemomab Corporate Overview - November 2022

 

Annual Report

Download

Chemomab 2021 Annual Report